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The first hum<m Papillam;; virus (HPV) vaccine ""'""
approved in the United Statetl in 2006 with the potentia] to
reduce cervical cancer and genital ·,>:3rts. Since then, its
effic:acy in preventing HPV-rdated cancers in both m,;}es
and female~ has been prom;sing. Despite CDC
recommcndmiuns, opponents of the vaccine a5sert that
V<:Jccinatir.g pre..<;dolesc:ents and adolescents wrU incre<,se
their sexual activity, a~ well as overtly c:ondo.ne risky sexui:ll
behavior. We analyzed clinic data cf 499 adoh:::;ct:ntt: vvith a
mean age of 16 years w c:xplorc v;hcther vc.cc:u;;Jtion kd to
change in sexual behavior after one year. Our results
showed no statis-tically significant difference i1~ either
initiation of sexual !lctivity or d1ange in sex.u8l behavior
when compared to peers, therefo;·e rd~;ling the asscrti<Jn
that this rncthml of preventative h(~altbcarc pronwk.s

promiscuity, Thus, we conclude that teenage sexual
behavior is linked more clnsely to ethics, morality, and
olher socio-cultural phenomena rather than H!'V vaccine
itself.
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Introduction
Tne lmman papillornavirns (HPV) is the

mo~t

comilJOri. sexua11y :.nmsrrdticd infection in the United
States (1). 11m virus specifically target:;: the stratified

epithelium of ~kin and mucous membranes. The
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infection can result in a spectrm:n of c.nnditions
irwh1ding skin and anogcnital w;;rts, varii1us
z_rwgenitaJ malignancies, and in wme cases -..s,ith
nongcnita1 manik~tations. \'\/hi!e there are more than
mie hundred subtypes of thu vints, the most common
incluJe the lo'V'i risk subtypes, 6 and
higher risk subtypes, 16 and 18. Jt is

these fm;r subtypes done xesnlt in more U1a.J.1
the cases of genital 'Narts, and about 70%
of cervical cancer (2A) .
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In 2006, the; first vaccine against HPV wa~:;
approve<,l by the Food and Drug i\dministration.
(FDA) for Dse in females aged 9 to 26 years old in a
t4rava!cnt form targeting s1.1bcypcs 6, ll , 16 ai!.d 18
(5). A bivalent vers:ion targeting types 16 and l R. wa.s
later approved. in 2009 for prevention of (:t:rvical
cam:e1· and other precancerous lesions, a.lso in fenu~.les
(6). As lll<:sc vaccines were made availabl~:, tbe
CDC's advisory committee on immunization practices
(ACIP)
concomitantly
tecommended
routine
vaccination of .females ll-12 years old, or catch up
vaccination i}; females aged 13-26 irrespective of
previous sexual activity, a:-> w ell as in rn:ale aged 9-26
(7 ,8); ultimately sparking a great debate across tP,e
world. Given that the last time the vaccine--c<mcer link
was realized in the 1980s '.:'lith the hepatitis B vat:cine
and hepatoccHular cancer, lho HPV vaccine was
viewed. with great promise.
The efficacy of the vaccine itself ill 1m:vcntion of
an array of cancers, including cervical, penile, 'Ylllva.r,
vaginal, and anal can~:~;r, and pr~cancerous lesions (911) woul.d at first glance s<:etn to outweigh any
possible disadvantages. Early shldies looki11g ut tbe
acceptabil~ty of the vaccine dcmi)nstratcd that nwst
parents were in favor of vaccinating their daughters
after certain criteria were achieved -including: whether
the parent Hnderstood its effectiveness, whether the
vaccin~ was recommended by a physician, an d
whether HPV infection was probable. Initial
roadblocks cited included co.st~ and concerns that
vaccination. promoted earlier sexual activity in young
girls (]2). Looking at the .last five years, very little has
changed in either of these obstacles. The price of
vacoination has remained high for those wi!h no
insurance Rnd OVL'r .18 years of age, totaling about
$360 for the series of three vaccinations. while the
cost ot oth~r childhood. vaccinations that prot('Ct
against m ultiple diseases arc all less than S50.
Likev.'ise, parents opposing vaccination remain
vigilant that early vaccination wit! botb increase their
child's sexual activity, allCl condone risky sexual
behavior (13) . Since CDC rew mn:It~ndations for this
particuiar vaccine arc fbr aJ.i older age group than
oth<~r childhood vaccinations, parents WO!TY aho\lt <'.:UY
PQ!'Sible questions their children rnay hav(',.
Accurately and responsibly fielding these questions is
~~{}ltle.thing plli-ents mo;:;t likely fear because of ideas it
l11a)i·ignite in young impressionable mincb (14).

There were many preconceptiom: about the H.PV
vaccine even prim to its re-lease in 2006. One study ir1
the late 1990s surveyed adolescent~ abo.ut hnw they
believed teenage behavior would change after receipt
of the vaccine. Surprisingly, 77% believed there
\Vould he a substatttial increase ~n. risky sexual
behavior {15). Tt is ca8y to ascerta·in thaf if adolescents
have rhis misconception, that even greater numbers <>f
parents would huve s1mi1ar notions f'.bout fhc vaccine.
Years after landmark trials demonstrated the link
between lli')V und cancer prevention, poor acceptance
of be vaccine continut~d., akrti:ng t iS to problems
reqwtmg fiuther atte.otlon. One study reported
iindings from telephone surveys of parents of young
girb m public schools aged ll ~ 18 years m
economically disad"\o·a.ntaged area:; in Los Angeles,
Californi.a b{~lween 2007-2008. More than two years
after the vaccine ·n'llcase, patents echoed earlier
sentiments that the vaccine may be hanttful, costly,
that their daughter wasn't old c;~ough to receive
protection against an STI, and that the vaccine may
lead to s'~xual activity (16). Additionally, 75% of
surveyed parents wore f.1.mi1iar wilh the HPV vaccine.
Of these, 75% were aware thr.t the1r daughter was
eligible for the vaccine, and thal it: would be mos t
beneficial prior ~o the uli.<:et of scxltal activity (16).
Thio; study clearly l;{ernonstrates ~hat even though the
public is educated about the ability and benefits of the
vaccine, misconceptions about its side effects rqnain
and need to be fi1rthcr adda~ssed. Future genemtiom1
would he hdter served if socio-cultural ptcs.sttrt;s di<l
not affe<.:t the prevention of cancer.
b thh study, we analyzed clinical daia to
investigate if the d aims of change in s~xyal behavior
following HPV va:c c:ination were tn1e.

l\tlethods
All paticnL-s in our adolescent medicine clinic a:re
screc11ed for all risk behaviors, including sexual
activity at lhQir hsilial visit, then the risk behaviors are
updated on each visit. Adok~cent female patient!'!
attending our· 11dolescent clinic who w ere also
receiving "the ITPV vaccine were chosen as
partidpat:t{ fi)t our retrospective study. We analyzed
the risk assessment fotms for quuJifyitlg females ut
various time :points including prio~· to vaccination,
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No s[gnijlcant change in sexur:l behavior ;, . .·
upon completion of the vaccination senes, and one
year later. This method provides c1inical data at
diff.erent time points with reference to vaccination,
allowing us to explore changes in sexuai behavior, A!.i
addesccnt girls who have received the ·v accine. were
ind\,.lde<! :!n the study. Sexual activity data prior to the

start of the vaccine series and at

year aHer

completioh <.if the series were analyzed.
However, such a methcu is nut "';itht)~lt
limitatiom~ a~s·umhlg that an outc.omes cnn be
measured through these ohser.red variahlcs even if
they arc partially affected by socio-e.r.viromnenta.l
sourc0s. lu other ·.vords, it negkct.....:; the social and
environmental influences on the dynamics .of teenage
behavior. Regardless, it is sliti usct'hL to explore the
assertion that vaccination \Vill lead to prom1scuijy
since our ob.servat.'iuns on sexual behavior are in the
san:1e indivi<'hJals. A simple comparison of sex\lal
act1yity at. these separate points in time can g-~1id e
future research. We present the results of itpplying a
non·paramenjc approach to comparing sexua.l
behavior in the same indivi dual~ .

Results
There were 499 female ;;dole.scents who rec-eive-d the
vaccine. At rhe ti.m e of the first vaccination, the
average age of the sample was 16.05 (sd'"'2,9.); 51.4%
of the sample \Vas not sexually active i.e. claiming to
have zero partners; the average age cf the sexually
inactive group was 14.89 (sd'-"·2.98); l2% ofthe.totai
wen; smok~:r~; 8% had abnormal PAP results; 6.8%
had prior diagnosis of BPV. 'fhc variabl~ 'numbe:r of
partners' was used to investigate ch<mge in sexual
behavior foUovvii1g vaccination.
Our firs t and most pressing question was whether
there was a signitk<mt c:hange in the samp1e's sexual
behavior folli)wing the vaccination, S~nc.e data
collecte-d is from the same:: individuals at different
points i.r: time, a matched (related samples) non~
parametric Vli1coxon signed nmk test was carried O\lt.
At time 1, the start of the vaccination scrie:-:,
51.4% of the sample claimed to be sexually inactive
by not having a partner. At th.t~ end of one y~:ar, 51 .2%
of the sample again claimed to be sexcmlly .inactlv(:.

Obviously; a change of 0.2% ·is insignificant and does
not wartant statisti<;al analysis. Additionally , one year

after vaccinatio:i, 2.-8% Qfse:X't:ally
act1v<t by having at least · one indtleJ;,
2l5% of !{c;nJalJy active bce.a me i:\activ¢ ·.
year; Agai.n, these arc relatively minor ·. •....... .
not warrant statistical analysi~.
·.. ·.··· · ·. •·
On the other end of the spcctnn:n .
analysis of the sexu aLl y active b>i"Otip. In.
22. .6o/~, of claimed to hn·ve three or more
•i•''l'
1• .Aft~V..L... one ye~..
~s •o
2''~~-:tr<tli(a ..
... .... ~ ). ~
·a... , rhis
..... ... u-i(·'(;f''·
" ·"",...""iS
~. "'
.~ ·
·.
Again, a change of 0.2% is very minQr and doe~ n\)l
warrant statistical analysis. Of those claiming to have
more than three paxtncn>, on" ycm· later 4.5% were
sexually inactive, Conversely, of those wlw had 3 or
more partners after one yca.r, 1.8% had none, 0.9%
had one, and 0.9% had 1 partners at time 1. Again,
these arc insignificant char;ges that do not require
fiuiher analysis.

IHscussion
The premise of this study is to explore the assc1iinn
that prevetllative health cate in the form of HPV
vaccination m prc-ad.olcscenl.ii \V11l lead tn
promiscuity. Two significant issues stem from this
assertion. Pir~>t, we begin to question the nature of
hea1thcare programs in the medical context, -and also
in tcrmli of ito;; morality and socio-cultural phenomena.
Second; we begin to question adolescents' ability to
make decisions. Both of these i.ssu~~s are extre.m~ly
complex, govemed ·b y dynarnks of human behavior
( 17,1 8) It is difficult to accurately quant;i.fy the effecti'.
of wntiimou~ (.!Xposurc to stxLHtl material ~ssociated
with the HPV vaccine in each distinctadolesc{!rit w.ha
m ay or may nol. have had any previous e·xposure .from
the media, personal experienc:es} p:rrcnts, or even
sexual education courses. How could \ Ve assess the
inter<~ction between this conLinuou~ background
exposure w]th health and social policies in ado.lcscent
care? And would this so called 'negative' publjcity
taint adoles-cents' decision making? In other \.VQrds, an

assertion that obviously a.~soci.ates a healli:care
program with sexual actiVity may in fact
coll.nterprodu~.:tivc and detrimental; by doing so,
increase exposure to sexu.al behavior, ign<lr~
adolescents' p rocess of decision making;
impminntly, make tlnsubstanliated a

.. .. .
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\Ve quantify sexual activity of adolescents
through the variable 'number of partners,' to explore
adolescent ~'exual behavior. However, this clinical
di1t3set is still limiting. The dataset used in this paper
pnly prov-ides number of partners as reported by the
participants at the time of each visit There is no
objective way
to
verify
this
infom1atimL
Nevertheless, <Ulalysi$ of our dataset stili yields the
important conclusion that es:,;entially sexually nonactive adolescents remain sexually inactive after
vaccinat!ons. Furthermore, there ts also some
indication~ that change in behavior may be it~ both
directions; a smaB proportion of those who had no
partners at time one app(:ar to have at lea~<t o11c
p;Hiner one year later •,vhich is. still less than would he
expected by age change, ar:d, c<mversely, a small
proportion of those wi!h at iea.st one pa:rtnc:r at !irne
one <tppear not to have a partner a year later. If these
results a<;curate1y ref1cct: adolescent behavior in the
general population, we presume that vaccination anrl
sexual behavior are unrcl<Jtcd. Moreover, WG
speculate that at least in the short tenn, the real issue
at hand is the ~:odal awl cultural facH1rs.
Based on tbc n;:sult" of this study, vaccinating
young girls with the HPV va~:cine does not alter their
sexual behavior in a significant maurwr. Considering
the health benefits of the vaccine, fear of a potential
change in sexual behavior which does not seem to
actually exist, should not get in the way of providing
the protection against serious illnesses that the
vaccine provides.
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